Skip to main content
NC State Home
Wolfpack Investor Network

javollm2

Nov 10, 2025

Invicta Water Eclipses $1,000,000 in Funding from WIN and Harbright Ventures

Invicta has developed a continuous flow, in-situ system that both removes and destroys PFAS from drinking water, wastewater, and industrial runoff, without producing toxic byproducts or secondary waste. Unlike traditional two-step approaches, Invicta’s technology captures and eliminates contaminants in a single, efficient process.

Oct 27, 2025

Forever Ends Here

Forever Ends Here is a cinematic short film about Invicta Water’s breakthrough technology that doesn’t just filter PFAS... it destroys it, for good. Filmed in North Carolina, this story reveals how Invicta’s team set out to solve the unsolvable and built the world’s first all-in-one system that captures, concentrates, and destroys “forever chemicals” (PFAS) forever.

Aug 18, 2025

WIN, Harbright Invest in Eventuall to Advance Next-Gen Fan Engagement

Eventuall, based in Los Angeles, California, is developing a platform for virtual fan engagement that emphasizes safety, scalability, and monetization for talent-driven online events. Unlike general-purpose platforms such as Zoom or Twitch, Eventuall is specifically designed to support ticketed personalized interactions, with features like advanced production tools and patented systems for backstage management and participant vetting.

Aug 1, 2025

Basic Research Leads to Market’s First All-Natural, EPA-Registered Insect Repellent

Mimikai’s repellent leverages the active ingredient undecanone — a naturally occurring chemical compound found in tomatoes, bananas and other fruits. The company’s groundbreaking product has been certified by the EPA to protect against mosquitoes for up to eight hours and against ticks for up to four hours.

Jul 31, 2025

Here are the “Angel Deals of the Week” from today’s issue of The Diligent Observer:

Invicta Water is developing a continuous flow system that removes and destroys PFAS contamination from drinking water, wastewater, and industrial runoff in a single process.

Jul 30, 2025

Cary pilot targets PFAs in drinking water

Invicta Water's Jordan Lake pilot has treated 11 million gallons, claiming to erase PFAS with no toxic waste. Cary will judge fall test data to see if it's a cheaper fix than carbon filters.

Jul 30, 2025

Cary testing way to remove ‘forever chemicals’ from Jordan Lake without waste

A blue shipping container perched on the shore of Jordan Lake hums day and night, pulling raw, muddy water into a maze of stainless steel pipes. Since April 1, the skid‑mounted system has treated nearly 11 million gallons, according to Steve Wilcenski, chief executive and co‑founder of Invicta Water. It is a pilot program, testing a new way to remove toxic chemicals from the water.

Jul 30, 2025

WIN and Harbright Invest in Invicta Water to Combat Nationwide PFAS Crisis

Invicta has developed a continuous flow, in-situ system that both removes and destroys PFAS from drinking water, wastewater, and industrial runoff, without producing toxic byproducts or secondary waste. Unlike traditional two-step approaches, Invicta’s technology captures and eliminates contaminants in a single, efficient process.

Apr 29, 2025

Cloud Infrastructure Startup Cosmonic Eyes Triangle for Expansion as WIN and Harbright Invest

Cosmonic is the creator of Cosmonic Control, a control plane for managing enterprise applications across any cloud, edge, or self-hosted Kubernetes deployment. Built on an incubating CNCF project, wasmCloud, Cosmonic Control integrates with modern Kubernetes-based ecosystems, but is not dependent upon them. Cosmonic Control reduces the high cost of building and maintaining applications by providing a unified control plane and single interface for managing applications.

Apr 17, 2025

SonoVascular wins Angel Capital Association 2025 Luis Villalobos Award

SonoVascular, Inc., a clinical stage medical device company focused on bringing to market its SonoThrombectomy™ System, a safer and more effective treatment of venous thromboembolism (VTE), was awarded the Angel Capital Association's 2025 Luis Villalobos Award in the Life Science category at the Summit of Angel Investing conference in Denver, CO.